Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

39.87 -2.43 (-5.74%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021

November 13, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Third Quarter 2021 Financial Results

November 09, 2021

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For November 9, 2021 ↗

November 09, 2021

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings...

Via Benzinga

Where Veracyte Stands With Analysts ↗

August 26, 2021

Over the past 3 months, 6 analysts have published their opinion on Veracyte (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia

November 05, 2021

From Veracyte, Inc.

Via Business Wire

New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis

November 03, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities

November 02, 2021

From Veracyte, Inc.

Via Business Wire

New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

October 26, 2021

From Veracyte, Inc.

Via Business Wire

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

October 25, 2021

From Veracyte, Inc.

Via Business Wire

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

October 14, 2021

From Veracyte, Inc.

Via Business Wire

New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

October 13, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

October 12, 2021

From Veracyte, Inc.

Via Business Wire

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

October 11, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

October 11, 2021

From Veracyte, Inc.

Via Business Wire

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

October 06, 2021

From Veracyte, Inc.

Via Business Wire

Is Veracyte Still a Buy After Its Recent Rally? ↗

October 05, 2021

Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.

Via The Motley Fool

Biotech Playbook Revisited As Technicals Weaken ↗

September 27, 2021

Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...

Via Talk Markets

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

September 14, 2021

From Veracyte, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs ↗

September 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...

Via Benzinga

Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market ↗

September 09, 2021

Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day.

Via Talk Markets

Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

September 01, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

August 31, 2021

From Veracyte, Inc.

Via Business Wire

Vaccine Victory ↗

August 24, 2021

Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson...

Via Talk Markets

Topics Economy

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year

August 23, 2021

From Veracyte, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 20, 2021

Gainers CASI Pharmaceuticals (NASDAQ:CASI

Via Benzinga

Veracyte Completes Acquisition of HalioDx

August 03, 2021

From Veracyte

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 30, 2021

Gainers Erytech Pharma (NASDAQ:ERYP) sha...

Via Benzinga

63 Biggest Movers From Friday ↗

August 02, 2021

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.